Introduction
============

Fatigue is a common condition that is caused by strenuous physical activity and harmful diseases, including grueling exercise ([@b1-etm-0-0-9072]) and cancer ([@b2-etm-0-0-9072],[@b3-etm-0-0-9072]). Although symptoms of fatigue can be eliminated and relieved by appropriate exercise in many cases ([@b4-etm-0-0-9072]), people of different nationalities, occupations and ages all experience fatigue due to current social pressure, such as work and competitive pressure. If left unchecked, fatigue not only reduces productivity and that quality of life but can also contribute to the progression of fatigue itself.

Mitochondria are important intracellular organelles that produce the adenosine triphosphate (ATP) required for the contraction of skeletal muscles in mammals. Previous studies have demonstrated that muscle mitophagy was associated with metabolic disorders, including obesity and skeletal muscle dyskinesia concomitant with Parkinson\'s disease ([@b7-etm-0-0-9072],[@b8-etm-0-0-9072]). Long-term and appropriate exercise have been found to increase plasticity and mitochondrial biogenesis in skeletal muscle. Mitochondria in skeletal muscle can also exhibit physiological adaptation from oxygen-dependent aerobic glycolysis to oxidative phosphorylation under anaerobic conditions ([@b9-etm-0-0-9072]). Skeletal muscles account for 30% of the body\'s weight in humans that serve as the storehouse of amino acids and carbohydrates, in addition to being the converter of chemical energy into mechanical energy ([@b10-etm-0-0-9072]). To maintain a satisfactory level of health and quality of life, a sufficient number of mitochondria in skeletal muscles is required. For both professional athletes and the general public, strength building and the maintenance of various types of movement or posture require healthy skeletal muscles ([@b11-etm-0-0-9072]). Increases in the number of mitochondria can improve the performance of professional athletes and the health of ordinary people. Indeed, a previous study has reported that chronic exercise can drive mitochondria biogenesis and fusion in skeletal muscles of healthy people who trained regularly for an extended period of time after a previously sedentary period ([@b12-etm-0-0-9072]). Notably, high-intensity exercise can lead to the excess autophagy of skeletal muscle mitochondria, by process by which damaged mitochondria are removed by autophagic lysosomal complexes ([@b11-etm-0-0-9072],[@b13-etm-0-0-9072]). However, a reduction in the number of mitochondria caused by excessive autophagy can lead to skeletal muscle weakness ([@b12-etm-0-0-9072]). Therefore, understanding the mechanism that lead to exercise-induced mitochondrial dysfunction can provide insights into novel treatment options for fatigue.

*Rhodiola crenulata* oral liquid (RCOL) is a widely applied agent in traditional Chinese medicine for the treatment of ailments such as altitude sickness and physical weakness ([@b14-etm-0-0-9072]). *Rhodiola crenulata* is an endangered species of perennial herbaceous plant from the *Crassulaceae* family that is distributed mainly in Tibet. In traditional Tibetan herbal medicine, it is believed to increase physical endurance ([@b15-etm-0-0-9072]), to confer anti-fatigue ([@b18-etm-0-0-9072]) and anti-hypoxia properties ([@b19-etm-0-0-9072]). Additionally, previous studies have reported that *Rhodiola crenulate*, specifically its main active ingredient, salidroside, have a diverse range of pharmacological effects, including anti-inflammatory ([@b20-etm-0-0-9072],[@b21-etm-0-0-9072]), neuroprotective ([@b22-etm-0-0-9072]), eyesight protective ([@b25-etm-0-0-9072]), anti-radiation ([@b26-etm-0-0-9072]) and anti-cancer activities ([@b27-etm-0-0-9072]). However, the potential effects of RCOL on exhaustive exercise (EE)-induced fatigue in skeletal muscle remain poorly understood. Therefore, in the present study, an established *in vivo* mouse model of muscle fatigue was used to investigate the potential anti-fatigue effects of RCOL administration, in addition to the underlying mechanism, specifically mitophagy.

Materials and methods
=====================

### Ethical statement

The present study was approved by The Animal Research Ethics Committee of Chengdu University of Traditional Chinese Medicine. All experimental protocols were performed in accordance with The Animal Care Guidelines, conforming to The Health Guide for the Care and Use of Laboratory Animals ([@b28-etm-0-0-9072]).

### Reagents

Commercial RCOL was purchased from Tibet Tibetan Medicine Group Co., Ltd. (authorization no. B20070002). Primary antibodies against PTEN-induced kinase protein 1 (PINK1; cat. no. BC100-494) were purchased from Novus Biologicals, LLC. Antibodies specific for Parkin (cat. no. 2132), ubiquitin (cat. no. 3933), LC3-II/LC3-I (cat. no. 4108), sequestosome 1 (SQSTM 1/p62; cat. no. 5114), citrate synthase (CS, cat. no. 14309), and GAPDH (cat. no. 5174) were obtained from Cell Signaling Technology, Inc.

Lactic acid (LA; cat. no. A019-2), creatine phosphokinase (CK; cat. no. A032), lactic dehydrogenase (LDH; cat. no. A020-1), malondialdehyde (MDA; cat. no. A003-1), superoxide dismutase (SOD; cat. no. A001-2), catalase (CAT; cat. no. A007-1), total anti-oxidative capability (T-AOC; cat. no. A015), succinate dehydrogenase (SDH, cat. no. A022), and Na^+^-K^+^-ATPase (cat. no. A070-2) activity detection kits were purchased from Nanjing Jiancheng Bioengineering Institute. Glycogen content detection kits (cat. no. BC0345) and 2.5% Gluta transmission electron microscope specimen fixative (cat. no. P1126) were provided by Beijing Solarbio Science & Technology Co., Ltd. Xylene, acetone, phosphoric acid, osmium acid, uranyl acetate, lead citrate and paraformaldehyde were purchased from Chengdu Chron Chemicals Co., Ltd.

### High performance liquid chromatography (HPLC) analysis of gallic acid, salidroside, tyrosol, catechin, caffeic acid and p-coumaric acid in RCOL

To quantify the main constituents in RCOL, gallic acid (cat. no. M-017-181216), salidroside (cat. no. H-040-170403), tyrosol (cat. no. L-042-180426), catechin (cat. no. E-011-180725), caffeic acid (cat. no. K-003-181216) and p-coumaric acid (cat. no. D-032-171216) were used as reference substances (all purchased at 98% purity from Chengdu Ruifen Si Biotechnology Co., Ltd.). The HPLC protocol was performed as described previously ([@b22-etm-0-0-9072],[@b29-etm-0-0-9072]). Briefly, a mixture of the reference substances (0.1306 g/ml gallic acid, 0.1394 g/ml salidroside, 0.0646 g/ml tyrosol, 0.0038 g/ml catechin, 0.1140 g/ml caffeic acid and 0.0222 g/ml p-coumaric acid) and RCOL were analyzed using the Agilent 1260 Infinity System (Agilent Technologies, Inc.). The samples were filtered through 0.45-µm microporous membranes, following which 10 µl of the sample was loaded onto a C~18~ chromatographic column (Inner diameter x length: 4.6x250 mm; particle size: 5 µm; cat. no. 5020-39033, Yili Scientific Instrument Co., Ltd.) and separated using an initial mobile phase consisting of 0.2% phosphoric acid solution and acetonitrile. Gradient elution was then performed using acetonitrile as follows: i) 7% for 0-8 min; ii) 7-13% for 8-27 min; iii) 13-15% for 27-30 min; iv) 15-18% for 30-45 min; and v) 18% for 45-70 min at a column flow rate of 0.5 ml/min and a temperature of 25˚C. The curve regression equation was obtained by diluting 1.306 mg/ml gallic acid, 1.394 mg/ml salidroside, 0.646 mg/ml tyrosol, 0.222 mg/ml p-coumaric acid, 1.114 mg/ml caffeic acid and 0.038 mg/ml catechin by 2, 4, 8 and 16 times, respectively. Corresponding peaks were determined at a wavelength of 275 nm.

### Animals

Male, six-week-old Institute of Cancer Research (ICR) mice (25±2 g) were provided by Chengdu Dashuo Experimental Animal Co., Ltd. The license number for the use of experimental animals is SYXK (Chuan) 2013-124. All mice were kept under standard conditions at 23±2˚C and 50-60% humidity, with a 12-h light/dark cycle. Mice with similar mean body weights were randomly divided and housed in groups of five animals per cage. They were provided with free access to standard diet and sterilized water. All animal experiments were approved by The Animal Care Committee of Chengdu University of Traditional Chinese Medicine.

### Loaded swimming test

A total of 50 mice were randomly divided into five experimental groups of ten mice each: i) Control group; ii) Exhaustive exercise group (EE); iii) Low-Dose group (RCOL-L; 1.02 ml/kg/day); iv) Medium-Dose group (RCOL-M; 3.03 ml/kg/day); and v) High-Dose group (RCOL-H; 6.06 ml/kg/day). Mice in the three RCOL groups were given ROCL by oral gavage once daily for two weeks. The nutritional information for RCOL is summarized in [Table I](#tI-etm-0-0-9072){ref-type="table"}. Mice in the control and EE groups were given a volume of sterilized water equivalent to the volume of RCOL administered according to the body weight of the mouse.

All mice except for those in the control group first underwent free swimming training without any loads in a single 20-min training session each day for 3 days, after which they were challenged with a loaded swimming test to establish EE-induced damage in the quadriceps, using a procedure previously described ([@b30-etm-0-0-9072]). Briefly, the swimming test was applied 1 h after the final dosing, with a lead weight \~5% of the mouse body weight attached at the base of the tails. All mice were challenged individually under the same conditions (water temperature, 25±1˚C; depth, 30 cm), where failure to come to the water surface for breathing within 10 sec was determined as a sign of exercise fatigue. At the end of the swimming trial, the mice were sacrificed by cervical dislocation. Subsequently, \~0.6 ml blood samples from the eyeball were collected, liver and quadriceps tissues were collected for further experiments. The workflow of the present experimental protocol is shown in [Fig. 1](#f1-etm-0-0-9072){ref-type="fig"}.

### Measurement of anti-fatigue biomarkers and glycogen synthesis ability in the mouse serum and quadriceps femoris

Serum samples from mice were obtained by centrifugation at 12,000 x g for 10 min at 4˚C. Levels of biomarkers associated with fatigue were measured in the serum (CK) or in the quadriceps femoris tissues of the hind legs (LA, LDH, MDA, SOD, CAT and T-AOC). Glycogen synthesis ability was assessed by measuring glycogen levels in the liver and quadriceps femoris tissues. In addition, CS, SDH and Na^+^-K^+^-ATPase activities were also measured in quadriceps femoris tissues. All analytes were measured according to the manufacturer\'s protocols.

### Histopathological estimations of quadriceps femoris

A portion of the quadriceps tissue (10x5x5 mm) was carefully dissected from mice in each of the treatment groups and fixed in 4% formaldehyde overnight at 25˚C. Paraffin blocks were then prepared after dehydration (75% ethanol for 6 h, 85% ethanol for 10 h, 95% ethanol for 4 h, anhydrous ethanol I and II for 2 h), clearing (dimethylbenzene xylene I and II for 20 min and 15 min, respectively) and wax impregnation for 3 h. The blocks were cut then into 5-µm sections using a rotary microtome (RM2235; Leica Microsystems GmbH), deparaffinized in xylene, rehydrated with deionized water at 25˚C for 20 min and stained with hematoxylin for 30 min and eosin for 5 min at 25˚C. Following the staining protocol, the quadriceps sections from five mice in each group were digitally captured using a bright field light microscope (magnification x200; CX22; Olympus Corporation) equipped with an image capture system (DM1000; Leica Microsystems GmbH). The number of muscle fibers was counted in each sample, where the cross-sectional area of 20 muscle fibers in three random fields was measured using Image-Pro Plus software version 6.0 (Media Cybernetics, Inc.).

### Ultrastructural analysis of mitochondria in the quadriceps femoris by transmission electron microscopy (TEM)

The quadriceps femoris was dissected further into 1-mm^3^ samples and fixed using a 2.5% Gluta transmission electron microscope specimen fixative (pH 7.2-7.4) for 4 h at 4˚C, following which they were rinsed three times for 15 min each with 0.1 M phosphate solution. The samples were then fixed at 25˚C with 1% osmium acid for 3 h and then rinsed again three times for 15 min each with 0.1 M phosphate solution. The samples were then dehydrated at 4˚C, using the following dehydration protocol: i) 50% ethanol for 15-20 min; ii) 70% ethanol for 15-20 min; iii) 90% ethanol for 15-20 min; iv) 90% ethanol and 90% acetone (1:1) for 15-20 min; v) 90% acetone for 15-20 min; and vi) 100% acetone at room temperature for 15-20 min three times. Embedding and solidification were then performed using SPI-Pon 812 embedding kit (Structure Probe, Inc.) overnight at 37˚C, then for 12 h at 45˚C and finally for 24 h at 60˚C. Ultrathin 50-60-nm sections were then cut using an ultramicrotome (EM UC7; Leica Microsystems GmbH), collected onto copper grids and stained for 5 min with 3% uranyl acetate and lead citrate at 25˚C. The grids were then washed with distilled water and viewed under a transmission electron microscope (magnification x10,000; JEM1230; JEOL) for the observation of the muscle tissue ultrastructure. A total 10 muscle cells in random non-overlapping fields per grid were considered for counting purposes and five grids were assessed in each group using Image-Pro Plus software version 6.0 (Media Cybernetics, Inc.).

### Western blot analysis

The quadriceps femoris of mice were dissected and immediately separated on ice. Tissue homogenate was obtained from the quadriceps femoris tissues using the FastPrep-24™ sample preparation system (MP Biomedicals, LLC) as described previously ([@b7-etm-0-0-9072],[@b31-etm-0-0-9072]). Total protein was isolated using a whole cell lysis assay (cat. no. KGP2100; Ken Gen Biotech. Co., Ltd.). A BCA protein assay kit (cat. no. AR0146; Boster Biological Technology) was used to evaluate the protein concentration of each sample. Equivalent amounts (40 *µg*/lane) of protein samples were separated by SDS-PAGE on 10% gels, following which they were transferred onto 0.45-µm PVDF membranes (cat no. IPVH00010, EMD Millipore). The membranes were then blocked with 5% non-fat milk for 2 h at 25˚C and incubated with primary antibodies against CS, PINK1, Parkin, LC3I/II, SQSTM-1/p62, ubiquitin and GAPDH overnight at 4˚C (all at 1:1,000 dilution). The membranes were then incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (1:1,000; cat. no. GB23303, Wuhan Servicebio Technology Co., Ltd.) for 2 h at 25˚C and washed with PBS containing 0.1% Tween-20 (cat. no. T8220; Beijing Solarbio Science & Technology Co., Ltd.) three times for 10 min each. Finally, Ultrasignal ECL electrochemiluminescent substrate (cat. no. 4AW011-100; Beijing 4A Biotech Co., Ltd.) was used for the visualization of the protein bands and images were captured using ChampChemi 610 Plus (Beijing Sage Creation Science Co., Ltd.). Density values of bands were calculated using Image-Pro Plus software version 6.0 (Media Cybernetics, Inc.) and normalized to GAPDH.

### Reverse transcription-quantitative PCR (RT-qPCR)

Total RNA was extracted from quadriceps femoris tissue using TRIzol^®^ according to manufacturer\'s protocol (Invitrogen; Thermo Fisher Scientific, Inc.). cDNA was subsequently synthesized by reverse transcription using a commercial Maxima SYBR Green Real-Time PCR kit (cat. no. KGA1339; Nanjing KeyGen Biotech Co., Ltd.) according to the manufacturer\'s instructions. RT-qPCR was performed in an ABI 7300 real-time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). All reactions were set up in 20 µl volumes using SYBR™ Green PCR Master Mix according to manufacturer\'s protocol (Applied Biosystems; Thermo Fisher Scientific, Inc.). The following thermocycling conditions were used for the qPCR: Initial denaturation at 95˚C for 30 sec; 40 cycles comprising denaturation at 95˚C for 5 sec, annealing at 60˚C for 30 sec and elongation at 72˚C for 30 sec; and final extension at 72˚C for 5 min. PINK1 and Parkin mRNA expression were normalized to those of GAPDH and presented as 2^-ΔΔCq^ ([@b34-etm-0-0-9072]). The primer sequences used are listed in [Table II](#tII-etm-0-0-9072){ref-type="table"}.

### Statistical analysis

Data are presented as the mean ± SD. Statistical analysis was performed using SPSS version 21.0 (IBM Corp.). Data were analyzed using one-way ANOVA followed by Tukey\'s multiple comparison post hoc test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Abundance of the six key compounds contained within RCOL

Detection and quantification of the six active compounds of RCOL (gallic acid, salidroside, tyrosol, p-coumaric acid, caffeic acid, and catechin) were first performed by HPLC. Concentrations were determined using the following curve regression equations: i) Gallic acid, *y*=5x10^7^*x*+942161, *r*=0.9992; ii) Salidroside, *y*=5x10^6^*x*-21828, *r*=1; iii) Tyrosol, *y*=10^7^*x*-19063, *r*=1; iv) p-coumaric acid, *y*=7x10^7^*x*-50372, *r*=1; v) Caffeic acid, *y*=5x10^7^*x*+115424, *r*=0.9999, and vi) Catechin, *y*=1x10^7^*x*-7681.9, *r*=0.9999. The relative abundance of the six compounds in RCOL are shown in [Fig. 2](#f2-etm-0-0-9072){ref-type="fig"} and [Table I](#tI-etm-0-0-9072){ref-type="table"}. Among them, the concentration of gallic acid and salidroside is the highest, at 1.8690 and 1.2709 mg/ml, respectively.

### Effects of RCOL administration on body weight of mice

The weight of the mice was recorded before and after RCOL treatment. Beyond the naturally increased body weight observed in mice, the continuous administration of RCOL for 14 days had no significant effects on body weight in the mice from each group by the end of the experiment ([Table III](#tIII-etm-0-0-9072){ref-type="table"}).

### Effects of RCOL administration on the levels of fatigue-related biomarkers in serum and quadriceps femoris tissues

After 2 weeks of RCOL pre-administration, the mice underwent 3 days of weight-free adaptive swimming training from day 12 onwards, once per day ([Fig. 1](#f1-etm-0-0-9072){ref-type="fig"}). On day 14, 1 h after RCOL administration, a weight-loaded swimming-induced skeletal muscle fatigue protocol was initiated on the mice, following which serum and quadriceps femoris samples were collected immediately after the end of the trial to detect changes in fatigue-related indicators. Compared with those in the EE group, significantly increased activities of SOD, CAT and T-AOC were observed in conjunction with significantly reduced LA, CK, LDH and MDA levels in the three different RCOL dosage groups ([Table IV](#tIV-etm-0-0-9072){ref-type="table"}). These results suggested that RCOL can relieve fatigue induced by EE in mice, possibly by modulating oxidative stress.

### Effect of RCOL administration on the histopathology and ultrastructure of quadriceps femoris in mice

A schematic diagram of the quadriceps femoris muscle structure in mice is presented in [Fig. 3A](#f3-etm-0-0-9072){ref-type="fig"}. Morphological analysis of skeletal muscle suggested that there was slight edema in the local muscle interstroma, looser connective tissue arrangement, irregular arrangement and shape of local muscle fibers. Meanwhile, a small amount of muscle fiber area was visibly reduced, and the spacing was slightly widened in the control group. By contrast, RCOL pre-administration appeared to alleviate the above pathological damages ([Fig. 3B](#f3-etm-0-0-9072){ref-type="fig"}). Ultrastructural analysis of the mouse quadriceps femoris using TEM further confirmed the protective effect of RCOL pre-administration on EE-induced injury ([Fig. 3C](#f3-etm-0-0-9072){ref-type="fig"}). Indeed, compared with the control group, the myofibrils of the quadriceps femoris in the EE group were found to be significantly damaged, disorganized, partially disintegrated and even dissolved, where the A- and H-bands appeared thinner or were missing. The partly or fully disintegrated mitochondrial cristae, mitochondrial swelling or even vacuoles were also visible. In addition, the skeletal muscles of the EE group showed abnormal ultrastructural changes, including disappearance of the I-band, a blurred, disordered arrangement of the Z-disk and serrated corrugation ([Fig. 3C1-2](#f3-etm-0-0-9072){ref-type="fig"}). However, other than the changes to the mitochondrial microstructure aforementioned, results from this experiment did not suggest any changes in autophagosomes. Collectively, based on the morphological and ultrastructural characteristics of the skeletal muscle, RCOL pre-administration can protect the skeletal muscle against injury induced by EE.

### Effect of RCOL administration on energy production in mice

To evaluate the effect of RCOL on energy production in mice, the contents of liver and muscle glycogen, in addition to the activities of SDH and Na^+^-K^+^-ATPase in the quadriceps femoris were measured by biochemical analysis. Furthermore, CS expression in quadriceps femoris tissue was measured by western blotting. Compared with those in the EE group, the mice in the three RCOL groups exhibited significantly higher liver and muscle glycogen content ([Fig. 4A](#f4-etm-0-0-9072){ref-type="fig"} and [B](#f4-etm-0-0-9072){ref-type="fig"}), significantly higher CS expression ([Fig. 4C](#f4-etm-0-0-9072){ref-type="fig"} and [D](#f4-etm-0-0-9072){ref-type="fig"}) and significantly higher SDH ([Fig. 4E](#f4-etm-0-0-9072){ref-type="fig"}), and Na^+^-K^+^-ATPase activity ([Fig. 4F](#f4-etm-0-0-9072){ref-type="fig"}). Therefore, enhanced ATP production may partially underlie the anti-fatigue effects of RCOL observed in mice following EE.

### Effects of RCOL administration on the expression of PINK1/Parkin signaling pathway components

To determine the effects of RCOL on PINK1/Parkin-mediated mitophagy, western blot analysis was performed to measure PINK1, Parkin, LC3-Ⅰ/LC3-Ⅱ, p62 and ubiquitin protein expression of mice quadriceps tissue ([Fig. 5A-F](#f5-etm-0-0-9072){ref-type="fig"}). To support this, mRNA expression levels of Parkin and PINK1 were measured by RT-qPCR ([Fig. 5G](#f5-etm-0-0-9072){ref-type="fig"} and [H](#f5-etm-0-0-9072){ref-type="fig"}). Compared with those in the control group, mice in the EE group displayed significantly higher expression levels of PINK1, Parkin, LC3-Ⅰ/LC3-Ⅱ, p62 and ubiquitin, proteins associated with mitophagy. RCOL pre-administration was found to significantly reverse this effect on the expression of proteins aforementioned. In addition, RT-qPCR results further confirmed the reduced mRNA expression levels of PINK1 and Parkin in the medium and high dose RCOL groups compared with those in the EE group. Altogether, these results suggest that RCOL may protect mice from EE-induced fatigue by inhibiting the expression of mitophagy-related proteins.

Discussion
==========

RCOL is a tonic containing an abundance of pharmacologically active ingredients and nutrients ([@b22-etm-0-0-9072]). In the present study, RCOL was found to improve EE-induced skeletal muscle fatigue in mice, increased antioxidant capacity and glycogen synthesis. The anti-fatigue effect of RCOL may be associated with the inhibition of mitophagy through the regulation of the PINK1/Parkin signaling pathway.

Previous studies have suggested that EE can induce damage through the production of reactive oxygen radicals ([@b35-etm-0-0-9072]). The imbalanced reduction-oxidation states in turn lead to muscle weakness and fatigue ([@b35-etm-0-0-9072]). LA is a metabolite found in skeletal muscle, where the rapid accumulation of LA can cause damage. CK serves an important role in energy transfer, muscle contraction and ATP generation. CK levels have been previously reported to positively correlate with the expression of tissue LDH ([@b38-etm-0-0-9072],[@b39-etm-0-0-9072]). EE has been found to disrupt the redox state, increase MDA expression and reduce the contents of SOD and CAT, aggravating oxidative damage to the skeletal muscle ([@b40-etm-0-0-9072],[@b41-etm-0-0-9072]). Therefore, LA, CK, LDH, MDA, SOD, CAT and T-AOC were chosen as biomarkers to evaluate the degree of fatigue and oxidation in response to RCOL in skeletal muscle after EE-induced fatigue. In the present study, RCOL administration was observed to inhibit the levels of LA, CK, LDH and MDA, whilst increasing expression of SOD, CAT and T-AOC in the quadriceps femoris tissue, without affecting body weight. These findings suggested that the anti-fatigue properties of RCOL were at least partly associated with its antioxidant effects.

In the present study, at the cellular and microstructural levels, morphological and ultrastructural analysis suggested that EE can disrupt the normal arrangements of skeletal muscle cells, with incomplete and poorly defined sarcolemma. Irregular arrangements of muscle fibers can deteriorate further, as demonstrated by the twisted, broken and dissolved muscle fibers, in addition to myostromal edema ([@b11-etm-0-0-9072]). It is also worth noting that unaccustomed exercise, in a manner that is dependent on both and intensity, can induce the acute microdisruption of the myofibrils and cytoskeletal structures ([@b42-etm-0-0-9072]). In addition, broken myofilaments, dilated sarcoplasmic reticula, disruptive mitochondrial structures, swollen and vacuolated mitochondria were previously observed in EE-induced skeletal muscle damage ([@b12-etm-0-0-9072]). The present study suggested that RCOL administration mitigated EE-induced skeletal muscle damage, preserved mitochondrial morphology and function, as evidenced by the restoration of the number and area of healthy muscle fibers and the amelioration of ultrastructural damage. However, the results of transmission electron microscopy of skeletal muscle mitochondria in the present study did not provide direct evidence of mitophagy. Future studies should aim to couple investigations of representative markers associated with autophagy, including lysosomes and autophagy-lysosome complexes, with changes to the skeletal muscle fiber and mitochondrial ultrastructure.

CS and SDH are two important catalytic enzymes involved in the tricarboxylic acid cycle. CS and SDH activities are higher in skeletal muscles with more mitochondria, thereby providing more ATP ([@b43-etm-0-0-9072]). Previous *in vitro* and *in vivo* studies suggested that, under normal conditions, *Rhodiola crenulata* extract (RCE) inhibited hepatic glycogen synthesis, reducing blood glucose levels through activation of the 5\'AMP-activated protein kinase (AMPK) signaling pathway ([@b44-etm-0-0-9072]). By contrast, another previous study reported contrasting results, where RCE treatment increased glycogen synthesis through the AMPK pathway in HepG2 cells incubated under high-glucose conditions ([@b45-etm-0-0-9072]). Therefore, to determine the effects of RCOL on energy production in mice with EE-induced fatigue, glycogen content was evaluated in the liver and quadriceps femoris tissues. RCOL treatment was found to increase glycogen levels in both tissues, possibly owing to enhanced gluconeogenesis process. The activities of CS, SDH and Na^+^-K^+^-ATPase in quadriceps femoris were also assessed. Higher CS, SDH and Na^+^-K^+^-ATPase activities were confirmed in RCOL-administered mice compared with those in the EE group. Collectively, these findings suggested that RCOL pre-administration increased glycogen content in the liver and muscle tissues, thereby augmenting ATP production. The motor ability and behavioral performance of mice were therefore improved, evidenced by enhanced energy production and improved fatigue-related indicators. Therefore, it may be concluded that RCOL can increase the glycogen content in response to EE. Further *in vivo* and *in vitro* studies are required to verify the regulatory effects and mechanisms of RCOL on glycogen synthesis under different conditions, such as diabetes.

Previous studies suggested that autophagy and/or mitophagy were involved in the physiological and pathological homeostasis of mitochondrial quality control in skeletal muscle cell ([@b13-etm-0-0-9072],[@b46-etm-0-0-9072],[@b47-etm-0-0-9072]). Parkin, encoded by the *Park2* gene in animals, is a cytoplasmic E3 ubiquitin ligase with broad physiological roles. It is highly expressed in skeletal muscle and other tissues, including the substantia nigra of brain, heart, liver and testis ([@b46-etm-0-0-9072]). PINK1 belongs to the Ser/Thr protein kinase family which contains a single protein kinase domain and is highly expressed in the mitochondrial outer membrane (MOM) of skeletal muscle. Reduced mitochondrial inner membrane electrochemical gradients, which are initiated by mitochondrial uncouplers or toxins, are required for ATP production. Subsequently, Parkin translocates from the cytosol into the mitochondria under conditions of impaired and imbalanced mitochondrial membrane potentials ([@b13-etm-0-0-9072]). Accumulation of PINK1 on the MOM, then phosphorylates Parkin on serine 65 to activate the ligase activity of Parkin, resulting in increased mitophagy ([@b48-etm-0-0-9072]). Additionally, Parkin conjugates ubiquitin chains on proteins located on the MOM, causing signal amplification and recruitment of the autophagosome to initiate mitophagy ([@b13-etm-0-0-9072]). Therefore, changes in the concentration of PINK1 protein can be used to measure the health status of mitochondria ([@b49-etm-0-0-9072],[@b50-etm-0-0-9072]). PINK1 and Parkin are considered to be the key mediators of mitophagy in removing damaged mitochondria from the cell ([@b51-etm-0-0-9072]).

SQSTM1/p62 is a ubiquitously expressed scaffold protein that is considered to be a marker of autophagosomes, which serve an essential role in the regulation of mitophagy ([@b13-etm-0-0-9072],[@b52-etm-0-0-9072]). p62 maintains its own intracellular levels by regulating the mitophagy process by directly binding to LC3, forming a LC3/p62 complex ([@b53-etm-0-0-9072]). Loss of p62 expression results in the inactivation of autophagy and the accumulation of cytoplasmic protein inclusions, thereby contributing to the progression of diseases associated with autophagy deficiency, including cancer and Parkinson\'s disease ([@b54-etm-0-0-9072]). In addition, PINK1/parkin-mediated mitophagy has also been found to be associated with ubiquitin and p62([@b55-etm-0-0-9072]). Previous studies suggested that salidroside suppressed bladder cancer cell growth by inhibiting the mechanistic target of the rapamycin (mTOR) pathway and translation initiation, whilst inducing autophagy in tumor cells ([@b56-etm-0-0-9072]). However, other previous studies have also suggested that salidroside can increase hypoxia and hydrogen peroxide-induced autophagy in pulmonary arterial smooth muscle cells and human umbilical vein endothelial cells through downregulation of mTOR signaling ([@b57-etm-0-0-9072],[@b58-etm-0-0-9072]). Salidroside has also been documented to inhibit autophagy in primary cortical neurons of neonatal Sprague-Dawley rats exposed to glutamate ([@b59-etm-0-0-9072]) and suppress the mitophagy process in the hippocampal CA3 neurons after chronic hypobaric hypoxia injury ([@b60-etm-0-0-9072]). Additionally, salidroside alleviated hepatic autophagy in mouse models of hepatic ischemia-reperfusion injury and hepatic fibrosis ([@b61-etm-0-0-9072],[@b62-etm-0-0-9072]). In the present study, western blotting results indicated that RCOL pre-administration inhibited the expression of PINK1, Parkin, LC3, p62 and ubiquitin. Further gene expression analysis conducted by RT-qPCR also suggested that RCOL could downregulate the expression PINK1 and Parkin mRNA. To the best of the authors\' knowledge, these results provided the first experimental evidence that RCOL could suppress the expression mitophagy-related proteins in the skeletal muscle following EE induction, including those in the PINK1/Parkin signaling pathway. The proposed molecular mechanism underlying the effects of RCOL pre-administration on alleviating fatigue in mice is presented in [Fig. 6](#f6-etm-0-0-9072){ref-type="fig"}.

In conclusion, the present study demonstrated that RCOL pre-administration exerted anti-fatigue effects and improved exercise performance in mice through the regulation of mitophagy-related markers in skeletal muscle including those of the PINK1/Parkin signaling pathway. However, the precise molecular mechanisms underlying the anti-fatigue properties of RCOL require further investigation.
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![Experimental workflow of the present study. RCOL, *Rhodiola crenulata* oral liquid; EE, exhaustive exercise; ICR, Institute of Cancer research; W, week.](etm-20-04-3161-g00){#f1-etm-0-0-9072}

![High performance liquid chromatography determination of the six major components contained within RCOL. (A) Chemical structures of the six mixed reference substances. (B) Determination of the relative content of the six main active components of RCOL. 1, gallic acid; 2, salidroside; 3, tyrosol; 4, catechin; 5, caffeic acid; 6, p-coumaric acid; RCOL, *Rhodiola crenulata* oral liquid.](etm-20-04-3161-g01){#f2-etm-0-0-9072}

![Effects of RCOL administration on the histology and ultrastructure of quadriceps femoris tissue of mice subjected to EE. (A) Schematic diagram of quadriceps femoris of mice tissues. (B) Hematoxylin and eosin staining observed by optical light microscopy. The black arrow indicates areas of reduced muscle fibers. Scale bar, 50 µm. (C) Ultrastructural analysis of mitochondria by TEM. (C~1~) Compared with the control group, (C~2~) mice in the EE group exhibited more areas of damaged mitochondria. (C~3-5~) Mice in the RCOL groups appeared to have less damaged ultrastructures with a comparable level of uniformity as that observed in the control group. Yellow arrows indicate the location of mitochondria. Red boxes indicate bright zones. The dark zone is located between the Z and M lines. Yellow boxes indicate H zones. Scale bar, 2 µm. n=5. RCOL, *Rhodiola crenulata* oral liquid; EE, exhaustive exercise; TEM, transmission electron microscopy; L, low dose; M, medium dose; H, high dose.](etm-20-04-3161-g02){#f3-etm-0-0-9072}

![Effects of RCOL administration on energy production in mice. (A) Liver and (B) muscle glycogen content. (C) CS protein expression was measured in quadriceps femoris tissue and (D) quantified by semi-quantitative analysis. (E) SDH activity in quadriceps femoris tissue. (F) Na^+^-K^+^-ATPase activity in quadriceps femoris tissue. Data are presented as the mean ± SD. n=6. ^\*\*^P\<0.01 vs. Control; ^\#^P\<0.05 and ^\#\#^P\<0.01 vs. EE. RCOL, *Rhodiola crenulata* oral liquid; EE, exhaustive exercise; L, low dose; M, medium dose; H, high dose; CS, citrate synthase; SDH, succinate dehydrogenase; ATP, adenosine triphosphate; prot, protein.](etm-20-04-3161-g03){#f4-etm-0-0-9072}

![Effects of RCOL administration on the protein and mRNA expression of key PINK1/Parkin signaling pathway components. (A) Representative western blotting images showing the protein expression of PINK1, Parkin, LC3-II/LC3-I, p62 and ubiquitin in mice quadriceps femoris tissues. Semi-quantitative densitometric analysis of (B) PINK1, (C) p62, (D) Parkin, (E) LC3I and (F) ubiquitin. Relative mRNA expression of (G) PINK1 and (H) Parkin, two key proteins associated with mitophagy. Data are presented as the mean ± SD. n=6. ^\*\*^P\<0.01 vs. Control; ^\#^P\<0.05 and ^\#\#^P\<0.01 vs. EE. RCOL, *Rhodiola crenulata* oral liquid; EE, exhaustive exercise; L, low dose; M, medium dose; H, high dose; PINK1, PTEN-induced kinase 1; LC3, microtubule associated protein 1 light chain 3.](etm-20-04-3161-g04){#f5-etm-0-0-9072}

![Proposed molecular mechanism for the effect of RCOL pre-administration on improved exercise performance in fatigued mice. RCOL, *Rhodiola crenulata* oral liquid; EE, exhaustive exercise; PINK1, PTEN-induced kinase 1.](etm-20-04-3161-g05){#f6-etm-0-0-9072}

###### 

Composition of *Rhodiola crenulata* oral liquid.

  Peak no.   Compound          Retention time (min)   Concentration (mg/ml)
  ---------- ----------------- ---------------------- -----------------------
  1          Gallic acid       9.557                  1.8690
  2          Salidroside       23.077                 1.2709
  3          Tyrosol           27.618                 0.5359
  4          Catechin          31.544                 0.0109
  5          Caffeic acid      36.232                 0.0989
  6          p-coumaric acid   46.943                 0.4086

###### 

Primers used for reverse transcription-quantitative PCR.

  Gene     GenBank accession no.   Primer sequence, 5\'-3\'
  -------- ----------------------- -----------------------------
  GAPDH    NM_017008.4             F, TCACTATTGGCAACGAGCGGTTC
                                   R, GCACTGTGTTGGCATAGAGGTCTT
  PINK1    NM_026880.2             F, CAGTGTAGAGCGTGGTGGCAAT
                                   R, AGGCACCGACTCAGGCATCT
  Parkin   NM_016694.4             F, GCTTGACACGAGTGGACCTGAG
                                   R, AACTGGACCTCTGGCTGCTTCT

F, forward; R, reverse; PINK1, PTEN-induced kinase 1.

###### 

Effect of RCOL administration on mouse BW.

  Title            Control      EE           RCOL-L       RCOL-M       RCOL-H
  ---------------- ------------ ------------ ------------ ------------ ------------
  Initial BW (g)   27.93±1.19   28.27±0.92   28.14±1.21   27.77±0.86   27.55±0.99
  Final BW (g)     35.50±2.11   35.85±1.22   35.25±1.75   32.24±2.11   31.28±1.44
  ∆BW (g)          7.50±1.70    7.60±0.93    7.10±1.72    4.50±1.97    3.70±1.81

Data are presented as the mean ± SD. n=10. RCOL, *Rhodiola crenulata* oral liquid; EE, exhaustive exercise; BW, body weight; L, low dose; M, medium dose; H, high dose.

###### 

Effect of RCOL administration on anti-fatigue indicators in the serum samples and quadriceps femoris tissue of mice.

  Sample               Parameter           Control        EE                                                         RCOL-L                                                      RCOL-M                                                      RCOL-H
  -------------------- ------------------- -------------- ---------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- -----------------------------------------------------------
  Serum                CK, U/ml            0.77±0.20      2.16±0.25^[a](#tfn1-etm-0-0-9072){ref-type="table-fn"}^    1.79±0.08^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^     1.55±0.05^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^     1.27±0.13^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^
  Quadriceps femoris   LA, mmol/g prot     0.51±0.07      1.29±0.19^[a](#tfn1-etm-0-0-9072){ref-type="table-fn"}^    1.00±0.083^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^    0.75±0.07^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^     0.69±0.06^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^
  Quadriceps femoris   LDH, U/g prot       1.26±0.11      1.98±0.18^[a](#tfn1-etm-0-0-9072){ref-type="table-fn"}^    1.76±0.08^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^     1.60±0.12^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^     1.55±0.12^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^
  Quadriceps femoris   MDA, nmol/mg prot   2.95±0.37      6.03±0.61^[a](#tfn1-etm-0-0-9072){ref-type="table-fn"}^    4.91±0.06^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^     4.48±0.14^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^     3.93±0.33^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^
  Quadriceps femoris   SOD, U/mg prot      158.77±12.95   87.86±5.21^[a](#tfn1-etm-0-0-9072){ref-type="table-fn"}^   110.82±5.94^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^   121.68±6.77^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^   140.39±4.14^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^
  Quadriceps femoris   CAT, U/mg prot      18.50±3.14     4.18±1.64^[a](#tfn1-etm-0-0-9072){ref-type="table-fn"}^    6.68±2.25                                                   7.71±1.90^[c](#tfn3-etm-0-0-9072){ref-type="table-fn"}^     14.44±3.12^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^
  Quadriceps femoris   T-AOC, U/mg prot    0.67±0.06      0.28±0.03^[a](#tfn1-etm-0-0-9072){ref-type="table-fn"}^    0.37±0.03^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^     0.46±0.04^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^     0.55±0.02^[b](#tfn2-etm-0-0-9072){ref-type="table-fn"}^

Data are presented as the mean ± SD. n=8.

^a^P\<0.01 vs. Control;

^b^P\<0.01 and

^c^P\<0.05 vs. EE. RCOL, *Rhodiola crenulata* oral liquid; EE, exhaustive exercise; L, low dose; M, medium dose; H, high dose; prot, protein; CK, creatine kinase; LA, lactic acid; LDH, lactate dehydrogenase; MDA, malondialdehyde; SOD, superoxide dismutase; CAT, catalase; T-AOC, total antioxidative capability.

[^1]: Dr Jing Zhang, Ethnic Medicine Academic Heritage Innovation Research Center, Chengdu University of Traditional Chinese Medicine, 1166 Liutai Street, Wenjiang, Chengdu, Sichuan 611137, P.R. China <31649123@qq.com>
